Fig. 1: Kinetics of antibody development against SARS-CoV-2 antigens over time. | Nature Microbiology

Fig. 1: Kinetics of antibody development against SARS-CoV-2 antigens over time.

From: Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Fig. 1

a, A cumulative frequency analysis describing the point of seroconversion for each individual in the cohort. Graph shows the percentage of individuals in the cohort who become IgM, IgA or IgG positive to S glycoprotein, RBD and N protein each day POS. A serum sample is considered positive when the OD is fourfold above background. b, OD values at 1:50 serum dilution for IgM, IgA and IgG against S glycoprotein, RBD and N protein over time. Each line represents one individual (n = 65). Severities 0–3 are shown in black and severities 4/5 in red. More than 300 pre-COVID-19 healthy control samples and >100 sera from PCR-confirmed SARS-CoV-2-infected individuals were previously used to develop and validate the ELISA setup6. The ELISAs were conducted once.

Back to article page